Drug Trial Radar · NCT01207414
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
Last checked: Nov 20, 2026Latest source record: Mar 15, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
501
Actual
Start
Aug 2010
Primary completion
Jan 2012
Study completion Jan 2012
Sponsor
- Lead sponsor
- NovartisNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 22, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the clinical outcome of two switching strategies to iloperidone treatment in adult subjects with schizophrenia who require a change in their current antipsychotic treatment of risperidone, olanzapine, or aripiprazole due to suboptimal efficacy and/or safety/tolerability reasons.
Conditions
- Schizophrenia
Interventions
iloperidoneDrug
Iloperidone tablets supplied at doses of 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg to achieve a target dose of 12-24 mg/day for 12 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Integrated Clinical Global Impression of Change (I-CGI-C) at Week 12Time frame: Week 12
Locations
59 sites in 1 country. Site status is shown where the registry gives one.
Birmingham Psychiatry Pharmaceutical Studies, Inc.
Birmingham, Alabama
Comprehensive Neuroscience
Cerritos, California
ATP Clinical Research Center, Inc.
Costa Mesa, California
Collaborative Neuroscience Network
Garden Grove, California
Apostle Clinical Trials, Inc.
Long Beach, California
Pacific Health Systems
National City, California
Pacific Research Partners
Oakland, California
Excell Research, Inc.
Oceanside, California
University of California, Irvine
Orange, California
CNRI San Diego
San Diego, California
Affiliated Research Institute
San Diego, California
Artemis Institute for Clinical Research
San Diego, California
Neuropsychiatric Research Center of Orange County
Santa Ana, California
Viking Clinical Research
Temecula, California
Collaborative Neuroscience
Torrance, California
The Hospital of Central Connecticut
New Britain, Connecticut
Comprenhensive Neuroscience
Washington D.C., District of Columbia
Amit K. Vijapura MD & Associates
Jacksonville, Florida
Scientific Clinical Research
North Miami, Florida
Atlanta Center for Medical Research
Atlanta, Georgia
Comprehensive Neuroscience
Atlanta, Georgia
Northwest Behavioral Research Center
Marietta, Georgia
Carman Research
Smyrna, Georgia
Institute for Behavioral Medicine
Smyrna, Georgia
Alexian Brothers Center for Mental Health
Arlington Heights, Illinois
Rush University Medical Center, Treatment Research Center
Chicago, Illinois
University of Illinois at Chicago
Chicago, Illinois
AMR - Baber Research, Inc.
Naperville, Illinois
Midwest Center for Neurobehavioral Medicine
Oakbrook Terrace, Illinois
Louisiana Clinical Research
Shreveport, Louisiana
Neurobehavioral Medicine Group, Clinical Trials Division
Bloomfield Hills, Michigan
Rochester Center for Behavioral Medicine
Rochester Hills, Michigan
Precise Research Centers
Flowood, Mississippi
St. Charles Psychiatric Associates - Midwest Research Group
Saint Charles, Missouri
Center for Emotional Fitness
Cherry Hill, New Jersey
CRI World Wide Clinical Research Company
Willingboro, New Jersey
Albuquerque Neuroscience
Albuquerque, New Mexico
Neurobehavioral Research
Cedarhurst, New York
Comprehensive Neuroscience
Fresh Meadows, New York
Division of Psychiatry Research - Zucker Hills Hospital
Glen Oaks, New York
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.